Company intelligence / Profile preview
Anviron
Not specified*, California, United Statesanviron.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Anviron’s lead candidate, ANV221, has demonstrated in vivo efficacy by reducing tumor size and suppressing metastases in pancreatic ductal adenocarcinoma models, outperforming standard-of-care drugs. It also shows promise in halting tumor growth and potentially reversing drug resistance in triple-negative and HER2+ breast cancers. The company has received Orphan Drug Designation from the FDA for ANV221 targeting pancreatic cancers and is advancing toward clinical trials
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of Tennessee Research Foundation (UTRF)University of Tennessee Health Science Center (UTHSC)
Beyond the preview
Go deeper on Anviron.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anviron.